XML 21 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900
Goodwill and Intangible Assets
6 Months Ended
Nov. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
GOODWILL AND INTANGIBLE ASSETS
Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between two and fifteen years, on either a straight-line basis or proportionately to the benefit being realized. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment, based on estimated future cash flows, whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
Goodwill and intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs based on respective fair market values at the date of acquisition.
For goodwill, the impairment test requires a comparison of the estimated fair value, based on future cash flows, of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge.
We consider our business to be a single operating segment entity, and a single reporting unit - the development, manufacture and sale on a global basis of medical devices for vascular access, peripheral vascular disease, oncology and surgery.
We test our goodwill balances during the third quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that an impairment may exist. Our stock market capitalization has at times been and as of November 30, 2015 continues to be lower than our shareholders’ equity or book value. However, our reporting unit has continued to generate significant cash flows from operations, and we expect to continue to do so in fiscal 2016 and beyond. Furthermore, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our stock market capitalization and our book value. Events could arise which may result in a future impairment charge which could be material to the consolidated financial statements.  Events that could, in the future, result in impairment include, but are not limited to, declining sales for a significant product or in a significant geographic region.
There were no adjustments to goodwill for the six months ended November 30, 2015. 
As of November 30, 2015 and May 31, 2015, intangible assets consisted of the following:
 
November 30, 2015
 
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
 
Weighted
avg useful
life
 
(in thousands)
 
(years)
Product technologies
$
148,390

 
$
(46,355
)
 
$
102,035

 
10.2
Customer relationships
86,322

 
(44,895
)
 
41,427

 
12.0
Trademarks
28,545

 
(4,696
)
 
23,849

 
10.7
In process R&D acquired
3,600

 

 
3,600

 
Indefinite
Licenses
7,913

 
(6,313
)
 
1,600

 
7.6
Distributor relationships
900

 
(900
)
 

 
3.0
 
$
275,670

 
$
(103,159
)
 
$
172,511

 
 

 
May 31, 2015
 
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
 
Weighted
avg useful
life
 
(in thousands)
 
(years)
Product technologies
$
148,776

 
$
(41,447
)
 
$
107,329

 
10.2
Customer relationships
86,371

 
(42,813
)
 
43,558

 
12.0
Trademarks
28,545

 
(3,229
)
 
25,316

 
10.7
In process R&D acquired
3,600

 

 
3,600

 
Indefinite
Licenses
7,913

 
(5,910
)
 
2,003

 
8.3
Distributor relationships
900

 
(900
)
 

 
3.0
 
$
276,105

 
$
(94,299
)
 
$
181,806